Bharathy, Narendra
Cleary, Megan M.
Kim, Jin-Ah
Nagamori, Kiyo
Crawford, Kenneth A.
Wang, Eric
Saha, Debarya
Settelmeyer, Teagan P.
Purohit, Reshma
Skopelitis, Damianos
Chang, Kenneth
Doran, Jessica A.
Kirschbaum, C. Ward
Bharathy, Suriya
Crews, Davis W.
Randolph, Matthew E.
Karnezis, Anthony N.
Hudson-Price, Lisa
Dhawan, Jyotsna http://orcid.org/0000-0001-7117-7418
Michalek, Joel E.
Ciulli, Alessio http://orcid.org/0000-0002-8654-1670
Vakoc, Christopher R.
Keller, Charles http://orcid.org/0000-0003-2505-7487
Article History
Received: 2 April 2021
Revised: 21 December 2021
Accepted: 20 January 2022
First Online: 29 January 2022
Competing interests
: The Ciulli Laboratory receives or has received funding from Almirall, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Nurix, and Ono Pharmaceuticals. AC is a scientific founder, shareholder, and consultant of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. CK is co-founder of Artisan Biopharma, a public benefit corporation pediatric cancer biopharma, as well as Tio Companies, and has received unrestricted grant support from Syndax Pharmaceuticals. CK also has research agreements with Roche/Genentech and Eli Lilly. All other authors declare no competing interests.